Salute e Benessere

Zealand Pharma announces directed issue and private placement for gross proceeds…

Company announcement – No. 1 / 2024Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT...
Nasdaq GlobeNewswire
08/01/2024

Safety Syringe Market to Surge at a CAGR of 4.5% by 2034 Amid Rising Preference…

Request Exclusive Sample Report: Safety Syringe Market Strategic Insights https://www.futuremarketinsights.com/reports/sample/rep-gb-18769 Request Exclusive Sample Report: Safety Syringe Market Strategic Insightshttps://www.futuremarketinsights.com/reports/sample/rep-gb-18769 Notable technological developments in the safety syringe industry have created creative and efficient safety measures. To provide better protection and simplicity of use, manufacturers are producing a variety of...
PR Newswire
08/01/2024

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in…

BioSenic signs a new subscription agreement for a maximum of EUR 1.2M in convertible bondsMont-Saint-Guibert, Belgium, January 8, 2024, 6pm CEST – BIOSENIC(Euronext Brussels and Paris: BIOS), the company addressing unmet medical needs in auto-immune diseases and orthopedics, today announces that it has signed a new subscription agreement for a maximum EUR 1.2 million convertible bonds ("CBs") facility, arranged by ABO Securities through its affiliated entity Global Tech Opportunities…
Nasdaq GlobeNewswire
08/01/2024

Ipsen – Half year statement – 2023 12 31

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHFBoulogne-Billancourt (France), January 8 th, 2024 –Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of December 31, 2023, the following resources were included to the dedicated liquidity account: 22,044 shares€2,808,813.12 It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account: 12,751 shares...
Nasdaq GlobeNewswire
08/01/2024

Enoxaparin Sodium Market Size to Grow USD 5354.7 Million by 2029 at a CAGR of…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-6L9458/Global_Enoxaparin_Sodium_Market_Insights_and_Forecast_to_2028 Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-6L9458/Global_Enoxaparin_Sodium_Market_Insights_and_Forecast_to_2028 Major Factors Driving the Growth of Enoxaparin Sodium Market : The 40 mg/0.4 mL dose offers a precise and manageable dosage, allowing for more efficient therapy and improved patient...
PR Newswire
08/01/2024

Medical Aesthetic Market is Estimated to be Worth USD 102.2 Billion by 2035…

LONDON, Jan. 8, 2024 /PRNewswire/ -- The medical aesthetic market is growing exponentially, anticipated to be worth USD 34.6 billion in 2023, and it is expected to reach USD 102.2 billion by 2035. The market will grow at a higher compounded annual growth rate (CAGR) of 9.4% during the forecast period from 2023 to 2035. LONDON,Jan. 8, 2024/PRNewswire/ -- The medical aesthetic market is growing exponentially, anticipated to be worthUSD 34.6 billionin 2023, and it is expected to...
PR Newswire
08/01/2024

Grief Counselling Market Size to Grow USD 4.52 Billion by 2029 at a CAGR of 7.8%…

Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-5D13128/Global_Grief_Counselling_Market_Research_Report_2023 Claim Your Free Sample Now:https://reports.valuates.com/request/sample/QYRE-Auto-5D13128/Global_Grief_Counselling_Market_Research_Report_2023 Major Factors driving the growth of Grief Counselling Market A number of variables, mostly related to the growing acceptability of mental health issues in general and grief-related mental health...
PR Newswire
08/01/2024

Tissue Diagnostics Market Worth $8.4 Billion | MarketsandMarkets

Browse in-depth TOC on "Tissue Diagnostics Market" Browse in-depth TOC on "Tissue Diagnostics Market" 172 - Tables 57 - Figures 240 - Pages Tissue Diagnostics Market Scope: In 2022, the Antibodies in the consumables segment is holds the largest share of the tissue diagnostics market, by product segment. The global tissue diagnostics market is divided into consumables (Antibodies, Kits, Reagents, and Probes) and Instruments (Slide-staining Systems, Scanners,...
PR Newswire
08/01/2024

New developments at Evosep to make clinical proteomics 100x more robust and 10x…

Proteomics as a toolbox is set to revolutionize drug discovery and precision medicine by providing unprecedented insights into the intricate molecular landscape of diseases and individual patient responses. Through the unique comprehensive analysis of protein isoforms expressed in cells, tissues, and body fluids, clinicians can identify specific biomarkers associated with various diseases, enabling earlier and more accurate diagnosis. This deeper understanding of molecular mechanisms facilitates…
PR Newswire
08/01/2024

Cell Counting Market to Reach $16.3 Billion, Globally, by 2032 at 7.7% CAGR…

Request Sample of the Report on Cell Counting Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/848 Request Sample of the Report on Cell Counting Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/848 Prime determinants of growth Technological advancements in cell counting instruments, rise in incidences of chronic and infectious diseases, and increase in funding for cell-based research are the factors driving the growth of the...
PR Newswire
08/01/2024

Global Rehabilitation Robots Market to Reach USD 1026.2 Million by 2030…

Get a Sample PDF of the Report: https://kingsresearch.com/request-sample/rehabilitation-robots-market-319 Get a Sample PDF of the Report: https://kingsresearch.com/request-sample/rehabilitation-robots-market-319 Competitive Landscape Major players operating in the global rehabilitation robots market are focusing on acquisitions as their key strategy to expand their business. For instance, inAugust 2023, ReWalk Robotics acquired AlterG to expand its business and speed up...
PR Newswire
08/01/2024

Suvoda Announces 30% Growth in 2023 Driven by Strong Customer Adoption of New…

Suvoda made significant investments in its technology platform and offerings in 2023, including the launch of a low-code/no-code application design layer. Organically built to deliver the next generation of Suvoda solutions, the Suvoda Platform was designed to handle complexity with ease, reduce overall risk throughout trials, and address real challenges facing clinical trial professionals. Built as the foundation for Suvoda IRT, eCOA and eConsent, the platform minimizes friction across the user…
PR Newswire
08/01/2024

Novaestiq Unveils Platform of Innovations; Poised to Disrupt the US Aesthetic…

"These pivotal developments signify our transition into a multi-product and practice-centric aesthetic company dedicated to customer excellence," shared Miles Harrison, Co-Founder, CEO & President. "With an expanded portfolio including two FDA-cleared products, two pending FDA submissions, and two candidates approaching Phase 3 trials, Novaestiq is set to realize its vision of Aesthetics for All™." "These pivotal developments signify our transition into a…
PR Newswire
08/01/2024

Evoke unveils simplified brand and structure: Inizio Evoke

"Building on our decades-long legacy of innovation, creativity, and impact in healthcare, our new unified brand reflects our commitment to our clients," said Reid Connolly, CEO of Inizio Evoke. "It is a natural evolution that removes barriers to collaboration and allows us to continue to deliver against the needs of our clients while leading change in the dynamic healthcare market. Under the banner of our bold new Inizio Evoke brand, we are better equipped to tap into Inizio's…
PR Newswire
08/01/2024

Evaxion Announces Plan to Implement ADS Ratio Change

/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”). The ADS Ratio Change is expected to...
Nasdaq GlobeNewswire
08/01/2024

Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs

Click here to view the custom infographic of the Lexaria Bioscience Corp. editorial. Click here to view the custom infographic of the Lexaria Bioscience Corp.editorial. GLP-1 agonists have emerged as the preferred weapons in the fight against diabetes, a disease affecting some 422 million people worldwide. Prolonged elevated blood sugar from diabetes results in significantly higher risk for serious comorbidities such as kidney disease, vision loss, heart and cardiovascular disease, and...
PR Newswire
08/01/2024

The World's First Clinical Base Edting Therapy for Hemoglobinopathy

Encompassing β-thalassemia and sickle cell diseases (SCD), hemoglobinopathies are the most common group of monogenic diseases in the world, with about 7% of the global population carrying the mutant gene. About 400,000 newborns are with hemoglobinopathies every year worldwide. β-thalassemia is a genetic disease caused by mutations in the β-globin gene, resulting in defective hemoglobin production. Correctseq's CS-101 is a personalized treatment that begins with the collection of autologous…
PR Newswire
08/01/2024

Novel Technology Transforms Baldness Treatment Using Beard and Body Hair

Across 82 patients with an average age of 48.9 years, the study consistently achieved graft attrition rates below 7% in BHT procedures, marking a significant advancement over prior technologies that reported damage rates as high as 20% (beard) and 30% (body). Impressively, all patients were satisfied with the procedure, with over 79% reporting high satisfaction six months post-procedure. Furthermore, surgeons, previously hesitant to perform BHT using traditional methods, enthusiastically embrace…
PR Newswire
08/01/2024

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema…

COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA 1cversus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetesBagsværd, Denmark, 8 January 2024– Novo Nordisk today announced topline results from the COMBINE 3 phase 3a trial of once-weekly IcoSema, a fixed-ratio combination of basal insulin icodec and semaglutide. COMBINE 3 was a 52-week, open-label treat-to-target...
Nasdaq GlobeNewswire
08/01/2024

Tecan to present at upcoming Investor Conferences

Männedorf, Switzerland, January 8, 2024– The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will attend and present at the following investor conferences this week: 42 ndAnnual J.P. Morgan Healthcare Conference, San FranciscoDate: 10 January 2024 Presentation: 09:00 am PST (6:00 pm CET) Presenter: Dr. Achim von Leoprechting, CEO, TecanAdditional participant: Tania Micki, CFO Webcast live under the "Investor Relations" tab of Tecan's websitewww.tecan.comA...
Nasdaq GlobeNewswire
08/01/2024

Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to…

Libtayo, which was invented using Regeneron's proprietary VelocImmune® technology, is currently approved by regulatory authorities in more than two dozen countries, including by the European Medicines Agency (EMA). In select markets, it is approved as monotherapy treatment for certain patients with advanced basal cell carcinoma (BCC), as monotherapy treatment for certain patients with advanced cutaneous squamous cell carcinoma (CSCC), as both monotherapy or in combination with chemotherapy for…
PR Newswire
08/01/2024

Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score...
Nasdaq GlobeNewswire
08/01/2024

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for…

Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), endpoints of Dry Eye Disease A clear and informed path now established for further development of drug through Phase 3 registration trials OK-101 exhibited placebo-like tolerability with a...
Nasdaq GlobeNewswire
08/01/2024

iTeos Announces 2024 Strategic Priorities and Anticipated Milestones

- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant's Phase 2 A2A-005 and EOS-984's Phase 1 trial- EOS-984 preclinical data demonstrating novel mechanism of action in the adenosine pathway anticipated in second quarter of 2024- Cash balance and investment balance of $644.9 million as...
Nasdaq GlobeNewswire
08/01/2024
Altri  Comunicati